Legend Biotech Corporation (LEGN)

Market Cap	6.68B +30.5%
Revenue (ttm)	1.14B +56.4%
Net Income	-250.10M
EPS	-1.38
Shares Out	185.74M
PE Ratio	n/a
Forward PE	46.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,859,091
Open	34.98
Previous Close	36.28
Day's Range	34.35 - 37.50
52-Week Range	16.24 - 45.30
Beta	0.35
Analysts	Buy
Price Target	56.39 (+56.73%)
Earnings Date	May 12, 2026

About LEGN

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lym...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 5, 2020
• Employees: 2,965
• Stock Exchange: NASDAQ
• Ticker Symbol: LEGN
• Website: https://legendbiotech.com

Financial Performance

In 2025, Legend Biotech's revenue was $1.03 billion, an increase of 64.02% compared to the previous year's $627.30 million. Losses were -$296.80 million, 67.7% more than in 2024.

Analyst Summary

According to 15 analysts, the average rating for LEGN stock is "Buy." The 12-month stock price target is $56.39, which is an increase of 56.73% from the latest price.

Price Target

$56.39

(56.73% upside)

Analyst Consensus: Buy